Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Operating expenses:
Research and development expense	$ 19,034	$ 7,849	$ 56,275	$ 43,828
General and administrative	9,359	3,772	29,233	9,463
Total operating expenses	28,393	11,621	85,508	53,291
Loss from operations	(28,393)	(11,621)	(85,508)	(53,291)
Other income (expense):
Interest income	719	6	892	16
Service fee income from related party				181
Change in fair value of derivative liability		(2,560)		(5,821)
Total other income (expense)	719	(2,554)	892	(5,624)
Loss from equity method investment in joint venture				(231)
Net loss and comprehensive loss	$ (27,674)	$ (14,175)	$ (84,616)	$ (59,146)
Net loss per common share - basic	$ (0.85)	$ (8.96)	$ (2.61)	$ (40.27)
Net loss per common share - diluted	$ (0.85)	$ (8.96)	$ (2.61)	$ (40.27)
Weighted average shares of common stock outstanding - basic	32,561,228	1,581,610	32,444,072	1,468,777
Weighted average shares of common stock outstanding - diluted	32,561,228	1,581,610	32,444,072	1,468,777